Payment overview · 2025
General Payments
$1,065.53
34 reported records · 14 companies
Healthcare provider profile · identity verified
Frederick A Burton, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MACON, GA · NPI 1912947326
Verified facts
What the public records show
CMS Open Payments records show Frederick A Burton, M.D. received $1,065.53 in general payments during 2025 across 34 reported records.
AstraZeneca Pharmaceuticals LP accounted for 41.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 310 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $437.06 | 41.0% | 11 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $138.27 | 13.0% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $127.27 | 11.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.38 | 6.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50.40 | 4.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.76 | 4.5% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $44.40 | 4.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $38.47 | 3.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.00 | 2.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.36 | 2.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.73 | 1.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.74 | 1.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.97 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.72 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,065.53 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $170.98 | 8 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $138.27 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $130.00 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $127.27 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.86 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $94.80 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $69.38 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $47.76 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.25 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $38.47 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 132 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 104 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 154 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 227 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 28 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 131 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
118 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
132 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
104 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
131 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
104 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
154 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
97 | 21 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
227 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
310 | 57 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1019 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 995 | 244 |
| Atorvastatin Calcium | Atorvastatin Calcium | 779 | 172 |
| Gabapentin | Gabapentin | 496 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 479 | 114 |
| Furosemide | Furosemide | 449 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 365 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 325 | 64 |
| Eliquis | Apixaban | 310 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 302 | 69 |
| Metformin Hcl | Metformin Hcl | 296 | 81 |
| Carvedilol | Carvedilol | 295 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 267 | 68 |
| Potassium Chloride | Potassium Chloride | 247 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 242 | 74 |
| Lisinopril | Lisinopril | 240 | 59 |
| Quetiapine Fumarate | Quetiapine Fumarate | 234 | 34 |
| Ozempic | Semaglutide | 227 | 41 |
| Trazodone Hcl | Trazodone Hcl | 227 | 49 |
| Omeprazole | Omeprazole | 218 | 59 |
| Losartan Potassium | Losartan Potassium | 215 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 214 | 39 |
| Alprazolam | Alprazolam | 205 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 201 | 50 |
| Tramadol Hcl | Tramadol Hcl | 192 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 190 | 37 |
| Simvastatin | Simvastatin | 190 | 38 |
| Meloxicam | Meloxicam | 177 | 44 |
| Allopurinol | Allopurinol | 175 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 49 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 171 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 164 | 26 |
| Mounjaro | Tirzepatide | 154 | 28 |
| Sertraline Hcl | Sertraline Hcl | 142 | 29 |
| Famotidine | Famotidine | 139 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 138 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 133 | 30 |
| Farxiga | Dapagliflozin Propanediol | 132 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 131 | 26 |
| Levetiracetam | Levetiracetam | 130 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 127 | 54 |
| Linzess | Linaclotide | 118 | 33 |
| Donepezil Hcl | Donepezil Hcl | 117 | 19 |
| Montelukast Sodium | Montelukast Sodium | 111 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 21 |
| Jardiance | Empagliflozin | 104 | 23 |
| Tradjenta | Linagliptin | 102 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 19 |
| Clonidine Hcl | Clonidine Hcl | 98 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 98 | 25 |
| Memantine Hcl | Memantine Hcl | 98 | 11 |
| Trulicity | Dulaglutide | 97 | 21 |
| Azelastine Hcl | Azelastine Hcl | 94 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 12 |
| Colchicine | Colchicine | 90 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 12 |
| Ibuprofen | Ibuprofen | 83 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 80 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 79 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 15 |
| Sucralfate | Sucralfate | 74 | 20 |
| Methylprednisolone | Methylprednisolone | 73 | 62 |
| Risperidone | Risperidone | 73 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 72 | 19 |
| Aripiprazole | Aripiprazole | 71 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 70 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 69 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 68 | 24 |
| Nifedipine Er | Nifedipine | 67 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 67 | 50 |
| Pregabalin | Pregabalin | 67 | 15 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 66 | 14 |
| Divalproex Sodium | Divalproex Sodium | 65 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 14 |
| Meclizine Hcl | Meclizine Hcl | 63 | 20 |
| Metformin Hcl Er | Metformin Hcl | 62 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 60 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 59 | 24 |
| Telmisartan | Telmisartan | 59 | 19 |
| Entresto | Sacubitril/Valsartan | 58 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 56 | 17 |
| Ondansetron Odt | Ondansetron | 55 | 25 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 54 | 11 |
| Fluconazole | Fluconazole | 54 | 37 |
| Levemir | Insulin Detemir | 54 | 12 |
| Amantadine | Amantadine Hcl | 51 | suppressed |
| Mirtazapine | Mirtazapine | 50 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 18 |
| Baclofen | Baclofen | 48 | suppressed |
| Clonazepam | Clonazepam | 48 | 13 |
| Glipizide | Glipizide | 47 | 11 |
| Prednisone | Prednisone | 47 | 11 |
| Rexulti | Brexpiprazole | 46 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | 13 |
| Levofloxacin | Levofloxacin | 45 | 36 |
| Valacyclovir | Valacyclovir Hcl | 45 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 11 |
| Naproxen | Naproxen | 44 | 16 |
| Latanoprost | Latanoprost | 43 | suppressed |
| Scopolamine | Scopolamine | 43 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 42 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 42 | 12 |
| Primidone | Primidone | 41 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 40 | suppressed |
| Bumetanide | Bumetanide | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 25 |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | 12 |
| Finasteride | Finasteride | 37 | 11 |
| Glipizide Er | Glipizide | 37 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 13 |
| Mupirocin | Mupirocin | 35 | 19 |
| Lacosamide | Lacosamide | 34 | suppressed |
| Novolog | Insulin Aspart | 34 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 12 |
| Nystatin | Nystatin | 33 | 15 |
| Insulin Lispro | Insulin Lispro | 32 | 11 |
| Rasagiline Mesylate | Rasagiline Mesylate | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Gemtesa | Vibegron | 31 | suppressed |
| Phenobarbital | Phenobarbital | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | 14 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 28 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 25 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Insulin Aspart | Insulin Aspart | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | 11 |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Methadone Hcl | Methadone Hcl | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 13 |
| Atenolol | Atenolol | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 13 |
| Metronidazole | Metronidazole | 18 | 12 |
| Pindolol | Pindolol | 18 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 17 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 17 | suppressed |
| Livalo | Pitavastatin Calcium | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 16 | suppressed |
| Humira(Cf) Pen | Adalimumab | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Misoprostol | Misoprostol | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Matzim La | Diltiazem Hcl | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Butrans | Buprenorphine | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,065.53 · 34 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, GEMTESA, IBSRELA, JARDIANCE, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error